Literature DB >> 15581969

Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.

William T Creasman1, Matthew F Kohler, Franco Odicino, Patrick Maisonneuve, Peter Boyle.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate patients with uterine papillary serous carcinoma (UPSC), clear cell (CC), and grade 3 endometrioid (G3) surgically stage I endometrial cancer.
METHODS: The 25th Annual Report (AR) of FIGO was used to identify patients with endometrial cancers who were surgically staged. For comparison, all cancers reported were evaluated with particular interest in patients with stage I UPSC, CC, and G3. Incidence, substage, post-surgical treatment, and survival were identified.
RESULTS: Of 5694 endometrial cancer patients reported to the AR, 3996 (70%) were surgically stage I. There were 148 UPSC, 59 CC, and 325 with G3 lesions. UPSC and CC represent 5.2% of all stage I cancers while 8.1% are G3. Although there were greater number of UPSC, CC, and G3 with extrauterine disease, about 50% of UPSC and CC were stage I. This compares to 81% for G1, 68% for G2, and only 42% for G3. There were more IA cancers with UPSC and CC than G3 (22%, 33%, and 17%, respectively). Survival (5 years) for UPSC and CC was 72% and 81%, respectively, compared to 76% for G3 lesions. Postoperative radiation improved survival somewhat (6-8%) but the difference was not significant.
CONCLUSION: UPSC and CC histotypes when diagnosed as stage I have a better survival than commonly perceived and equal to G3 endometrioid cancers. Postoperative radiation improves survival but not significantly so. The role of chemotherapy has not been defined.

Entities:  

Mesh:

Year:  2004        PMID: 15581969     DOI: 10.1016/j.ygyno.2004.08.019

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  54 in total

1.  Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.

Authors:  Shannon D Armbruster; Rebecca Previs; Pamela T Soliman; Shannon N Westin; Bryan Fellman; Anuja Jhingran; Nicole D Fleming
Journal:  Gynecol Oncol       Date:  2019-06-18       Impact factor: 5.482

Review 2.  Improving oncologic outcomes for women with endometrial cancer: realigning our sights.

Authors:  Sean C Dowdy
Journal:  Gynecol Oncol       Date:  2014-02-20       Impact factor: 5.482

3.  Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma.

Authors:  Minsi Zhang; T Jonathan Yang; Neil B Desai; Deborah DeLair; Marisa A Kollmeier; Vicky Makker; Mario M Leitao; Nadeem R Abu-Rustum; Kaled M Alektiar
Journal:  Brachytherapy       Date:  2018-10-10       Impact factor: 2.362

4.  Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients.

Authors:  Ji Young Park; Joo-Hyun Nam; Young-Tak Kim; Yong-Man Kim; Jong-Hyeok Kim; Dae-Yeon Kim; Insuk Sohn; Shin-Wha Lee; Chang Ohk Sung; Kyu-Rae Kim
Journal:  Virchows Arch       Date:  2013-02-17       Impact factor: 4.064

5.  Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.

Authors:  Ngai Na Co; David Iglesias; Joseph Celestino; Suet Y Kwan; Samuel C Mok; Rosemarie Schmandt; Karen H Lu
Journal:  Cancer       Date:  2014-07-16       Impact factor: 6.860

6.  Is adjuvant radiotherapy necessary for FIGO stage 1a grade 2 endometrial endometrioid adenocarcinoma?

Authors:  Abdurrahman Hamdi İnan; Gülçin Şahin Ersoy; Yusuf Yıldırım; Tutku Gürbüz; Ayşe Gül Kebapçılar; Merih Hanhan
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-07-14

7.  A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium.

Authors:  Anuja Jhingran; Lois M Ramondetta; Diane C Bodurka; Brian M Slomovitz; Jubilee Brown; Lawrence B Levy; Michael E Garcia; Patricia J Eifel; Karen H Lu; Thomas W Burke
Journal:  Gynecol Oncol       Date:  2013-02-04       Impact factor: 5.482

8.  Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?

Authors:  Flora Zagouri; George Bozas; Eftichia Kafantari; Marinos Tsiatas; Nikitas Nikitas; Meletios-A Dimopoulos; Christos A Papadimitriou
Journal:  Obstet Gynecol Int       Date:  2010-02-02

9.  Interobserver Variability in the Diagnosis of Uterine High-Grade Endometrioid Carcinoma.

Authors:  Sumi Thomas; Yaser Hussein; Sudeshna Bandyopadhyay; Michele Cote; Oudai Hassan; Eman Abdulfatah; Baraa Alosh; Hui Guan; Robert A Soslow; Rouba Ali-Fehmi
Journal:  Arch Pathol Lab Med       Date:  2016-05-03       Impact factor: 5.534

10.  Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.

Authors:  Oluwole Fadare; Wenxin Zheng; Marta A Crispens; Howard W Iii Jones; Dineo Khabele; Katja Gwin; Sharon X Liang; Khaled Mohammed; Mohamed M Desouki; Vinita Parkash; Jonathan L Hecht
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.